Søreide J A, Lea O A, Kvinnsland S
Dept. of Surgery, Rogaland Central Hospital, Stavanger, Norway.
Breast Cancer Res Treat. 1991 Dec;20(1):25-32. doi: 10.1007/BF01833354.
Several biochemical parameters quantitated in tumor cytosols from malignant breast tumors have been evaluated as possible prognostic factors. Cytosol protein content has always been regarded as a reference parameter, to correct for cellularity and representativity of tumor samples. But recent studies have suggested an altered protein distribution in malignant tissues. The present study on 382 women with histologically proven breast cancer, Stage I and Stage II, therefore evaluates whether cytosol protein content by itself may add information as a prognostic factor in the clinical management of breast cancer. Cytosol protein content was found to be significantly correlated (p less than 0.001) to tumor size, and inversely correlated to progesterone receptor (PgR) content (p = 0.015) and age at operation (p = 0.021). Using the median value of protein (4.15 mg/ml) as a cut-off value, two groups could be constructed. The number of node-positive patients in the protein-poor group was significantly decreased (p = 0.018) compared to the protein-rich group, which also contained a significantly (p less than 0.001) lower number of patients with estrogen receptor (ER) positive tumors (i.e. ER greater than or equal to 10 pmol/g). An increased number of events was observed in the protein-rich group (p less than 0.001), with a great contribution to the number of deaths due to breast cancer. In a multivariate analysis of the likelihood to predict axillary nodal involvement, protein category was found to be a significant (p less than 0.031) independent predictive factor. As to relapse free survival (RFS), protein category did not reveal any prognostic power.(ABSTRACT TRUNCATED AT 250 WORDS)
对来自恶性乳腺肿瘤的肿瘤胞质溶胶中定量的几种生化参数作为可能的预后因素进行了评估。胞质溶胶蛋白含量一直被视为一个参考参数，用于校正肿瘤样本的细胞数量和代表性。但最近的研究表明恶性组织中的蛋白质分布发生了改变。因此，本研究对382例组织学确诊为I期和II期乳腺癌的女性进行评估，以确定胞质溶胶蛋白含量本身是否可作为乳腺癌临床管理中的一个预后因素提供额外信息。发现胞质溶胶蛋白含量与肿瘤大小显著相关（p<0.001），与孕激素受体（PgR）含量呈负相关（p = 0.015），与手术年龄呈负相关（p = 0.021）。以蛋白的中位数（4.15 mg/ml）作为临界值，可分为两组。与蛋白丰富组相比，蛋白贫乏组中淋巴结阳性患者数量显著减少（p = 0.018），蛋白丰富组中雌激素受体（ER）阳性肿瘤患者数量也显著较少（p<0.001）（即ER≥10 pmol/g）。在蛋白丰富组中观察到事件数量增加（p<0.001），对乳腺癌死亡人数有很大影响。在预测腋窝淋巴结受累可能性的多变量分析中，蛋白类别是一个显著（p<0.031）的独立预测因素。至于无复发生存期（RFS），蛋白类别未显示任何预后能力。（摘要截断于250字）
